Johnson & Johnson: Multiple Myeloma trials

The registry lists 123 Multiple Myeloma studies with Johnson & Johnson as lead sponsor. 14 are open to participants now and 34 have results posted.

Phase 1 27Phase 2 37Phase 3 34Phase 4 4No phase 26(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Retreatment Study With Bortezomib for Multiple MyelomaCompletedNCT01030302
• Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.CompletedNCT01026701
• Quality of Life in Multiple Myeloma Patients Treated With BortezomibCompletedNCT01021592
• Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)CompletedNCT01005628
• A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00912899Phase 1
• A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma PatientsNo longer availableNCT00799539
• A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00752518Phase 1/2
• A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2
• A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsCompletedNCT00561743Phase 2
• VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the NetherlandsCompletedNCT00440765
• Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple MyelomaCompletedNCT00440635
• ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.CompletedNCT00440479
• An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaCompletedNCT00431769Phase 2
• A Study of Bortezomib as Consolidation Therapy in Patients With Multiple MyelomaCompletedNCT00416273Phase 3
• Consolidation Therapy With Bortezomib in Elderly Patients With Multiple MyelomaCompletedNCT00416208Phase 3
• A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1
• An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00402181Phase 2
• Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00344422Phase 3
• The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving ChemotherapyCompletedNCT00270166Phase 3
• The Effect of Epoetin Alfa on the Anemia of Patients With Multiple MyelomaCompletedNCT00270101Phase 3
• An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyCompletedNCT00216697Phase 2
• Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00095680Phase 2
• Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00087867Phase 2